BEZALIP SR 400 MG — DIN 02083523
BEZAFIBRATE : 400 MG · ALLERGAN INC · TABLET (EXTENDED-RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is BEZALIP SR?
BEZALIP SR 400 MG contains BEZAFIBRATE : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02083523, held by ALLERGAN INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 03-Dec-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BEZALIP SR used for?
BEZALIP SR (bezafibrate) is indicated as an adjunct to diet and other therapeutic measures for: Treatment of patients with hypercholesterolemia Type IIa and IIb mixed hyperlipidemia, to regulate lipid and apoprotein levels (reduce serum TG, LDL cholesterol and apolipoprotein B, increase HDL cholesterol and apolipoprotein A). Treatment of adult patients with high to very high triglyceride levels, Fredrickson classification Type IV and V hyperlipidemias, who are at a high risk of sequelae and complications (i.e. pancreatitis) from their dyslipidemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Bezafibrate cost around the world?
Bezafibrate is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Saudi Arabia publishes a public; South Africa publishes a single exit price; United Arab Emirates publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| South Africa | single exit price | 5 | 5 |
| United Kingdom | hospital | 2 | 2 |
| Saudi Arabia | public | 2 | 2 |
| United Arab Emirates | public | 1 | 1 |
10 pack listings across 10 brand entries and 3 price bases, refreshed 01 Sep 2026. Ranges span every Bezafibrate pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Bezafibrate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Bezafibrate, across 5 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ALLERGAN INC | 1 | 1 | BEZALIP SR | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | JAMP-BEZAFIBRATE SR | Sourceable in Canada |
| ACTAVIS GROUP PTC EHF | 1 | 0 | ACT-BEZAFIBRATE SR | No marketed DIN |
| HOFFMANN-LA ROCHE LIMITED | 1 | 0 | BEZALIP TAB 200MG | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-BEZAFIBRATE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 400 MG |
|---|---|
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | blister packs of 30 |
| Storage | Store at room temperature (15-30 °C). Protect from high humidity. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Bezafibrate |
|---|---|
| ATC code | C10AB02 |
| AHFS class | 24:06.06 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02083523 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2083523 |
| Brand name | BEZALIP SR |
| Generic / active ingredient | BEZAFIBRATE : 400 MG |
| Market authorization holder | ALLERGAN INC |
| Health Canada schedule | Prescription |
| ATC code | C10AB02 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C10AB |
| Current status | MARKETED |
| Status date | 03-Dec-2020 |
| Original market date | 1994-12-21 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
One 400 mg sustained release tablet once daily, taken in the morning or evening with or after meals. Swallow whole without chewing.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hepatic/renal impairment, gallbladder disease, hypersensitivity to fibrates, photoallergic reactions, pregnancy/lactation, Type I hyperlipoproteinemia, combination with statins in high-risk patients.
Warnings and precautions
Risk of myositis/rhabdomyolysis (especially in renal impairment). Monitor liver function and blood counts. May lead to cholelithiasis. Discontinue if CPK >10x ULN or gallstones found.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP-BEZAFIBRATE SR | 400 MG | Tablet | JAMP PHARMA CORPORATION | MARKETED | 02453312 |
| ACT-BEZAFIBRATE SR | 400 MG | TABLET (EXTENDED-RELEASE) | ACTAVIS GROUP PTC EHF | CANCELLED PRE MARKET | 02379414 |
| BEZALIP TAB 200MG | 200 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | 02084082 |
| PMS-BEZAFIBRATE | 200 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | 02240331 |
2 · Same class — other molecules in ATC C10AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Fenofibrate | AA-FENO-MICRO · AA-FENO-SUPER · AVA-FENOFIBRATE MICRO · DOM-FENOFIBRATE MICRO · +33 more | 56 | 10 | Yes |
| Bezafibrate | ACT-BEZAFIBRATE SR · BEZALIP SR · BEZALIP TAB 200MG · JAMP-BEZAFIBRATE SR · +1 more | 5 | 2 | Yes |
| Gemfibrozil | APO-GEMFIBROZIL · APO-GEMFIBROZIL CAP 300MG USP · DOM-GEMFIBROZIL · GEMFIBROZIL CAP 300MG · +13 more | 22 | 1 | Yes |
| Clofibrate | ATROMID S CAP 500MG · ATROMID-S 1GM · ATROMID-S CAP 500MG · NOVO-FIBRATE CAP 500MG | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C10A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C10AA | Atorvastatin · Cerivastatin · Fluvastatin · Lovastatin · Pravastatin · +2 more | 759 | 286 |
| C10AX | Alirocumab · Dextrothyroxine · Evinacumab · Evolocumab · Ezetimibe · +5 more | 48 | 28 |
| C10AC | Colesevelam · Colestipol · Colestyramine | 29 | 6 |
| C10AD | Nicotinic Acid | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is BEZALIP SR called?
The same molecule, Bezafibrate, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Bezachole Sr | Latin | South Africa |
| Bezalip | Latin | South Africa |
| Bezalip Retard | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.